N9289

NVP-231

≥98% (HPLC)

• Synonym(e): N-[2-(benzoylamino)-6-benzothiazolyl]-Tricyclo[3.3.1.13,7]decane-1-carboxamide, adamantane-1-carboxylic acid (2-benzoylamino-benzothiazol-6-yl)amide
• Empirische Formel (Hill-System): C₂₅H₂₅N₃O₂S
• CAS-Nummer: 362003-83-6
• Molekulargewicht: 431.55
• NACRES: NA.77
• PubChem Substance ID: 329818618
• UNSPSC Code: 12352200
• MDL number: MFCD01988824
• Assay: ≥98% (HPLC)
• Form: powder

Eigenschaften

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to off-white
• solubility: DMSO: >10 mg/mL
• originator: Novartis
• storage temp.: 2-8°C
• SMILES string: O=C(Nc1nc2ccc(NC(=O)C34C[C@H]5C[C@H](C[C@H](C5)C3)C4)cc2s1)c6ccccc6
• InChI: 1S/C25H25N3O2S/c29-22(18-4-2-1-3-5-18)28-24-27-20-7-6-19(11-21(20)31-24)26-23(30)25-12-15-8-16(13-25)10-17(9-15)14-25/h1-7,11,15-17H,8-10,12-14H2,(H,26,30)(H,27,28,29)/t15-,16+,17-,25-
• InChI key: MVSSJPGNLQPWSW-CIRRPZLZSA-N

Beschreibung

Biochem/physiol Actions

Ceramide kinase presents an attractive target for drug development because of its involvement in cell growth and inflammation.

Ceramide kinase presents an attractive target for drug development because of its involvement in cell growth and inflammation. CerK biology is still poorly understood thus discovery and availability of inhibitors will facilitate research at this area. NVP-231 is a newly discovered potent, specific and reversible CerK inhibitor that competitively inhibits binding of ceraminde to CerK.

Features and Benefits

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Sicherheitshinweise

• Lagerklasse: 11 - Combustible Solids
• wgk: nwg
• flash_point_f: Not applicable
• flash_point_c: Not applicable